20140110 - Jan 10, 2014
ISSUE 2 – JAN. 10, 2014PDF

Orlando Hospital Severs MD Anderson Ties,
Forming Center with University of Florida

On Jan. 30, somebody will have to climb to the top of Orlando Health’s 10-story Charles Lewis Pavilion to cover up—or start removing—the backlit letters that, with a halo effect created by LED lights, broadcast the health system’s affiliation with MD Anderson Cancer Center.

The name of the distant, venerable cancer center will vanish from Orlando’s skyline. The distinctive red swoosh that symbolically negates the word “cancer” will be gone also.

photoOrlando Health President Mark Roh:
We Opted For a Florida-Centric Strategy

Orlando Health is choosing a partnership over an affiliation, said Mark Roh, president of the Florida cancer center that’s ending its relationship with MD Anderson Cancer Center. Instead, Roh’s hospital is joining the University of Florida to create the UF Health Cancer Center at Orlando Health.

photoLudwig Cancer Research Donates
$540 Million to Six Centers

Ludwig Cancer Research donated a total of $540 million to six of its centers, located at institutions across the country.

photoAVEO’s Tivozanib Fails In Colorectal Cancer

AVEO Oncology said that data from a planned interim analysis of the phase II BATON (Biomarker Assessment of Tivozanib in ONcology) study in patients with colorectal cancer indicate that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population. 

photoTask Force Issues Guideline On LDCT Lung Screening

The U.S. Preventive Services Task Force released its final recommendation statement on screening for lung cancer with low-dose computed tomography.

photoACS: Decline in Death Rates Saved
Over 1.3 Million Lives

Declines in death rates over past two decades have added up to a 20 percent drop in the overall risk of dying from cancer, according to the American Cancer Society’s annual statistics report.

photoIn Brief

  • Gary Lyman to co-direct Fred Hutch outcomes research

  • Gary Schwartz named chief of NewYork-Presbyterian/Columbia University Medical Center Division of Hematology/Oncology 

  • Richard Gannotta named president of Northwestern Memorial Hospital

  • NCI Director Harold Varmus wins Medal of Honour from International Agency for Research on Cancer


FDA News

  • Accelerated Approval granted for Mekinist-Taflinar combination

  • European Commission amends Erbitux label

  • FDA and EMA launch joint initiative for generics inspections

20140103 - Jan 2, 2014
ISSUE 1 – JAN. 3, 2014PDF

Who Makes This Drug?
Secretive Contract Manufacturing Arrangements Complicate Solutions to Shortages of Generics

By Rena M. Conti
The closing of Ben Venue Laboratories, a company that produces a large share of generic drugs used by America’s oncologists, brings into focus a little-understood business practice that exacerbates the problem of drug shortages and shows why the industry and federal regulators have been unable to resolve them.

photoReport to the Nation: Death Rates Continue To Decline Across All Major Disease Sites

Death rates continued to decline for all cancers combined for men and women of all major racial and ethnic groups and for most major cancer sites, according to the Annual Report to the Nation on the Status of Cancer. Rates for both sexes combined decreased by 1.5 percent per year from 2001 through 2010.

photoAn Appreciation: Janet Rowley, “Translational Research Pioneer”

Janet Rowley, a pioneer in connecting the development of cancer with genetic abnormalities, died from complications of ovarian cancer on Dec. 17 at her home. She was 88.

photoIn Brief

  • Julie Vose Elected President of ASCO
  • 2014 Breakthrough Prize Winners Announced
  • Andrea Sloan, Prominent Ovarian Cancer Patient Dies
20131217_4 - Dec 17, 2013
ISSUE 46 – DEC. 13, 2013PDF

CPRIT Official Indicted for Skipping Peer Review

By Paul Goldberg
A grand jury in Travis County, Texas, indicted a former official of the Cancer Prevention and Research Institute of Texas for bypassing peer review in awarding an $11 million grant to a Dallas-based company.

photoWhy I Don’t Want to Pay for Your Horoscope:
Reflections on FDA Warning to 23andMe

Guest Editorial by Jim Evans
There’s been much recent gnashing of teeth (at least within the narrow and rather insular world of do-it-yourself genomics) about the gall of the FDA in choosing to issue a warning letter to 23andMe, effectively shutting down marketing of their direct-to-consumer personal genomic profiling. And adding to 23andMe’s woes, a class action suit has been filed against them.

photoBipartisan Deal Eases Some Budget Cuts By Extending Sequestration Through 2023

By Matthew Bin Han Ong
The House of Representatives voted 332-94 to approve a two-year budget outline Dec. 12 that would cancel $63 billion in sequester cuts for 2014 and 2015—in exchange for extending sequestration through 2023.

photoIn Brief

  • Thomas Burke stepped down as executive vice president and physician-in-chief at MD Anderson Cancer Center
  • Edward Jackson named chair of the Department of Medical Physics at the University of Wisconsin School of Medicine and Public Health
  • David Chang appointed professor of plastic surgery at the University of Chicago School of Medicine
  • Steve Mackin named chief operating officer of Cancer Treatment Centers of America